UBS analyst Lu Li raised the firm’s price target on Veracyte (VCYT) to $48 from $42 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
- Veracyte’s Strong Financial Performance and Growth Prospects Justify Buy Rating and Increased Price Target
- Veracyte Reports Strong Q3 2025 Financial Performance
- Veracyte reports Q3 adjusted EPS 51c, consensus 32c
- Veracyte raises FY25 revenue view to $506M-$510M from $496M-$504M